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The concentraƟ ons were 
higher than the concentraƟ ons of 
all paƟ ents ever tested with MCC/IMS. 
Furthermore, a peak P-77.2/0.601 was found, 
which decreased aŌ er few weeks of therapy and 
needs further biochemical characterisaƟ on. 
Parallel GC/MSD invesƟ gaƟ ons suggest (S)-(+)-6-Methyl-
1-octanol[110453-78-6], Cyclohexanone, 5-methyl-2-(1-
methylethyl)- [10458-14-7], Benzaldehyde, 2,5-dimethyl- 
[5779-94-2], Ethanone, 1-(4-methylphenyl)- [122-00-9], 
Dodecane [112-40-3] or Decanal [112-31-2]. 
These preliminary data show that breath analysis 
in paƟ ents with metabolic disorders might give 
further informaƟ on about metabolism, 
especially under enzyme replace-
ment therapy. 
PaƟ ent Father Mother
Hunter disease is 
a mucopolysaccharidosis for 
which enzyme replacement therapy 
with idursulfase has been oﬀ ered for 3 ye-
ars. Therapy can be monitored by the urinary 
concentraƟ on of dermatan sulfate and heparin sul-
fate. A 38-year-old male person suﬀ ering from Hun-
ter disease has been treated with idursulfase for a year, 
showing dramaƟ c clinical improvement. AddiƟ onally, 
the paƟ ent had breath analysis using MCC/IMS 
every week before enzyme replacement. The 
paƟ ent showed increasing concentraƟ ons 
of a peak P-1.5/0.547 which is rela-
ted to acetone [67-64-1] over 
the Ɵ me.
